Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.73 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.64 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.61 |
| ▸ | GHSR | Q92847 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070940 | 1.00 | DPP4 (0.73) | DPP4CHRM1GPR119POU2F2ADORA3 | |
| SCHEMBL3893713 | 0.94 | DPP4 (0.70) | DPP4CHRM1GPR119POU2F2ADORA3 | |
| SCHEMBL3891025 | 0.92 | DPP4 (0.72) | DPP4CHRM1GPR119 | |
| SCHEMBL3892163 | 0.91 | DPP4 (0.71) | DPP4CHRM1GPR119POU2F2ADORA3 | |
| SCHEMBL3894488 | 0.91 | DPP4 (0.66) | DPP4CHRM1GPR119 | |
| SCHEMBL3889624 | 0.91 | DPP4 (0.68) | DPP4CHRM1GPR119 | |
| SCHEMBL3906086 | 0.91 | DPP4 (0.70) | DPP4CHRM1 | |
| SCHEMBL3904026 | 0.90 | DPP4 (0.79) | DPP4CHRM1GPR119POU2F2ADORA3 | |
| SCHEMBL4668631 | 0.90 | DPP4 (0.68) | DPP4CHRM1CHRM3 | |
| SCHEMBL3904016 | 0.90 | DPP4 (0.79) | DPP4CHRM1GPR119POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560450-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2009-07-14 | — | — | US | claimed |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| EP-2322152-A1 | Method of preparing a composition comprising a GPR119 agonist | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322157-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322150-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322151-A2 | Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7560450-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2009-07-14 | — | — | US | disclosed |
| EP-1808168-B1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1997484-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 1644/4885GPR119 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.